The cell and gene therapy (CGT) industry is moving toward a future where coordination, not just capability, defines success. As therapies scale, organizations across the supply chain are discovering an essential truth: no single stakeholder can operate independently. Manufacturers, clinics, couriers, quality teams, and sponsors all contribute to a treatment journey that must be carefully aligned, compliant, and predictable. Yet despite the industry’s progress, collaboration remains one of the toughest challenges in CGT operations. Variations in scheduling, inconsistent documentation, and manual SOP execution often create administrative delays that limit therapy availability. When each stakeholder works in its own system, even …